New combo therapy aims to heal fragile skin
NCT ID NCT06834035
Summary
This study is testing if adding an IV immunoglobulin (IV IgG) treatment to an existing gene therapy (VYJUVEK) helps wounds heal better in people with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe genetic skin condition. The main goal is to see if this combination reduces wound size and improves quality of life. It will involve 8 participants who are already receiving VYJUVEK treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGRedwood City, California, 94163, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.